Clinical trials: High Risk Cancer
Prostate Cancer
Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis
One of the biggest problems facing prostate cancer patients and their treating physicians is who needs to be treated and when. Common clinical and pathological parameters are useful (PSA, Gleason score, etc.) but do not clearly…
- Trial name
- NCT01350180
- Where
- 8 sites in Canada
- Sponsor
- Dr. Tamim Niazi
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)
The study will be an open label, single arm, phase I study intended to identify the safety and tolerability of "AML Cell Vaccine" given to eligible MDS RAEB-2 and AML patients who have achieved a best response of complete…
- Trial name
- NCT02493829
- Testing
- AML Cell Vaccine
- Volunteers
- 10 people
- Sponsor
- King's College London
Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor
Cilengitide in Treating Children With Refractory Primary Brain Tumors
This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors.
- Conditions
- Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Ependymoblastoma
- Trial name
- NCT00063973
- Testing
- cilengitide, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, High Risk Superficial
Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer
This is a phase II study. This means that BCG therapy has already been found to be safe in humans. The investigators just want to see if using more treatments works better.
- Trial name
- NCT02281383
- Testing
- Bacillus Calmette-Guérin (BCG)
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-Cell Prolymphocytic Leukemia, Hypodiploidy
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
This phase II trial studies autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in treating patients with high-risk Hodgkin lymphoma, non-Hodgkin lymphoma, multiple myeloma, or chronic…
- Conditions
- B-Cell Prolymphocytic Leukemia, Hypodiploidy, Loss of Chromosome 17p, Plasma Cell Leukemia
- Trial name
- NCT01008462
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Stem Cell Transplantation
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
To evaluate the feasibility and efficacy of a autologous stem cell transplantation followed by a Melphalan/ Fludarabine based dose-reduced allograft from HLA-identical and HLA-compatible unrelated donor in patients with Multiple…
- Trial name
- NCT00781170
- Testing
- allogeneic hematopoietic SCT
- Volunteers
- 20 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma
This phase I trial studies how well vismodegib after stem cell transplant works in treating patients with high-risk first remission or relapsed multiple myeloma. Vismodegib may slow the growth of cancer cells.
- Conditions
- DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01330173
- Testing
- Vismodegib, Pharmacological Study, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
- Trial name
- DIM Vidaza (NCT05218902)
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Bristol-Myers Squibb
Medulloblastoma, Glioblastoma Multiforme
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS
- Trial name
- NCT04978727
- Testing
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Where
- 14 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Glioblastoma Multiforme
Evaluating Therapeutic Response to Novo-TTF
This study is to assess the utility of high resolution 3D echo planar magnetic resonance spectroscopy (3D EPSI) in monitoring Novo-TTF response in glioblastoma multiforme (GBM) patients.
- Trial name
- NCT02441322
- Testing
- Novo-TTF
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI
Objectives: In this Radboud University Nijmegen Medical Centre (RUNMC) initiated study our first objective is to investigate toxicity (safety and feasibility) of vaccination with frameshift-derived neoantigen-loaded DC of CRC…
- Trial name
- NCT01885702
- Testing
- DC vaccination
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR)
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
KEYNOTE-177 is currently the only randomized controlled phase III clinical trial evaluating the efficacy and safety of pembrolizumab versus standard chemotherapy combined with targeted first-line therapy for dMMR/MSI-H metastatic…
- Conditions
- Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H)
- Trial name
- NCT05426005
- Testing
- Cadonilimab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Prostate Cancer Screening
MRI Screening in Men at High Risk of Developing Prostate Cancer
The purpose of this study is to determine whether or not Magnetic Resonance Images (MRI) will identify high-grade cancers earlier and more frequently in men at high risk of developing prostate cancer.
- Trial name
- NCT05608694
- Testing
- Prostate MRI
- Where
- 2 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Chicago
Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
To see if it is possible to use short-duration tacrolimus after a peripheral blood stem cell transplant in certain malignancies that are considered difficult to engraft.
- Conditions
- Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT02556931
- Testing
- Fludarabine, Cyclophosphamide, Total body irradiation
- Where
- United States
- Volunteers
- 117 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Risk (Above Average) Subjects, Non Compliant Patients for Colo Rectal Cancer [CRC] Screening
Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects
The purpose of this study is to establish the efficacy of Check-Cap's C-Scan System in providing structural information on colonic polypoid lesions and masses, as an adjacent tool to Feacal Immunochemical Test [FIT] in high risk…
- Conditions
- High Risk (Above Average) Subjects, Non Compliant Patients for Colo Rectal Cancer [CRC] Screening, Counterindicated Patients for Colonoscopy
- Trial name
- NCT03356002
- Testing
- C-Scan System
- Where
- 7 sites in Israel
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Check-Cap Ltd.
Multiple Myeloma
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population.
- Trial name
- BEAM (NCT03570983)
- Testing
- Allopurinol, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Swedish Medical Center
Myeloma
Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as…
- Trial name
- NCT06947083
- Testing
- Elranatamab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastric Cancer
Bi-Weekly Docetaxel Plus 24-Hour Infusion of High-Dose 5-Fluorouracil / Leucovorin (HDFL) for Inoperable Advanced or Metastatic Gastric Cancer
The primary objective is to determine the tumor response rate of bi-weekly docetaxel plus 24-hour infusion of high-dose 5-FU/leucovorin chemotherapy for patients with inoperable advanced gastric cancer.
- Trial name
- NCT00155883
- Testing
- Taxteral, 5-Fluorouracil, Leucovorin
- Where
- Taiwan
- Volunteers
- 54 people
- Sponsor
- National Taiwan University Hospital
Acute Myeloid Leukemia, in Relapse, Myelodysplastic Syndromes
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome
This is a multicenter, open-label Phase 1 study of orally administered CB-5339 in participants with R/R AML or participants with R/R intermediate- to high-risk MDS.
- Trial name
- NCT04402541
- Testing
- CB-5339
- Where
- 10 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Cleave Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.